A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn’s Disease
Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Edward V. Loftus(Mayo Clinic), Ursula Seidler(Medizinische Hochschule Hannover), Keith Friedenberg, Sally Zhao(Gilead Sciences (United States)), Scott D. Lee(University of Washington), Corey A. Siegel(Dartmouth–Hitchcock Medical Center), Ke Wang(Tianjin Medical University Cancer Institute and Hospital), Emily Wendt(Gilead Sciences (United States)), Bal Raj Bhandari(Ironwood Pharmaceuticals (United States)), John S. Sundy(Gilead Sciences (United States)), Matt McKevitt(Gilead Sciences (United States)), Ziad Younes(American College of Veterinary Surgeons)
Cited by 51
Related Papers
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
ACG Clinical Guideline: Ulcerative Colitis in Adults
|The American Journal of Gastroenterology|2019|1.6k